Us2.ca vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Us2.ca

by Us2.ai

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

Us2.ai automates comprehensive echocardiography analysis to enhance diagnostic accuracy and workflow efficiency for various cardiac conditions. In contrast, Tempus ECG-AF utilizes AI to analyze 12-lead ECGs, specifically identifying patients aged 65 or older at increased risk of developing new-onset atrial fibrillation within 12 months. While both are cardiology AI tools, Us2.ai focuses on imaging interpretation, whereas Tempus ECG-AF provides risk prediction for a specific arrhythmia.

Choose Us2.ca if…

Choose Us2.ai if your cardiology department requires a comprehensive, fully automated solution for echocardiography analysis, aiming to significantly reduce manual interpretation time and enhance diagnostic consistency across a broad spectrum of cardiac conditions. This tool is ideal for facilities seeking to generate detailed, structured cardiac reports in seconds, improving workflow efficiency and supporting the detection of various structural and functional heart diseases.

View Us2.ca →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your clinical focus is on proactive risk stratification for new-onset Atrial Fibrillation in patients aged 65 or older. This AI-based algorithm is specifically designed to analyze standard 12-lead ECGs to identify individuals at increased risk of developing AF within the next 12 months, enabling earlier intervention and follow-up in a defined elderly population.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Us2.ca	Tempus ECG-AF
Pricing	Unknown	Contact vendor
Deployment	Vendor-neutral across GE, Philips, Siemens, Canon and handheld POCUS.	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Us2.ca

Us2.ca emphasizes 'zero clicks' and 'fully automated' echocardiography analysis, significantly reducing manual effort and processing time to deliver structured reports in seconds. Tempus ECG-AF, while valuable, requires clinical interpretation in conjunction with other diagnostic information, indicating a less automated workflow for the end-user.

Clinical Value

Us2.ca

Us2.ca offers broader clinical value by automating comprehensive echocardiography analysis for multiple cardiac conditions, including disease detection for Cardiac Amyloidosis, Heart Failure, Aortic Stenosis, and Pulmonary Hypertension, enhancing diagnostic accuracy and workflow efficiency across a wider spectrum of cardiac care. Tempus ECG-AF provides highly specific value in predicting AF risk in a defined patient population, which is important but narrower in scope.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF explicitly outlines CMS reimbursement codes (CPT 0764T and CPT 0765T) and a Medicare rate, providing clear financial transparency and a direct pathway for cost recovery for healthcare providers. Us2.ca's pricing is undisclosed, making its value proposition less transparent and harder to assess without direct vendor engagement.

Enterprise Readiness

Us2.ca

Both tools demonstrate strong enterprise readiness with HIPAA compliance and BAA availability. However, Us2.ca offers more explicit flexibility with both cloud and on-premise deployment options and broader stated compatibility with 'any ultrasound device and PACS manufacturers,' along with integration into PACS, CVIS, and EMR systems, suggesting a more adaptable solution for diverse enterprise environments.

Innovation

Tempus ECG-AF

Tempus ECG-AF introduces a novel predictive capability by being the first FDA-cleared 'cardiovascular machine learning-based notification software' to identify patients at increased risk of new-onset atrial fibrillation within 12 months from a standard ECG. While Us2.ca's full automation of echocardiography is highly innovative for efficiency and accuracy, Tempus ECG-AF's predictive nature represents a new diagnostic paradigm.

Support & Docs

Us2.ca

Us2.ca provides more comprehensive information regarding support and documentation, including a dedicated contact page with multiple channels (email, phone, form), a stated response time, and readily available IT/procurement resources and a user manual. Tempus ECG-AF offers clear contact information for technical support but less detail on available documentation or broader support resources.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Us2.ca	Tempus ECG-AF
Name	Us2.ca	Tempus ECG-AF
Primary Function	Fully automates echocardiography analysis, delivering comprehensive, structured cardiac reports.	Analyzes 12-lead ECG recordings to identify patients at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Categories	Cardiology AI, Radiology & Imaging AI	Cardiology AI
Specialties	Cardiology, Radiology	Cardiology, Geriatrics, Internal Medicine
Target Patient Population/Criteria	Not specified	Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

Videos

Demos, reviews, and walkthroughs featuring Us2.ca and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications and target conditions for each AI tool?

Us2.ai fully automates echocardiography analysis, delivering comprehensive cardiac reports and detecting diseases like Cardiac Amyloidosis, Heart Failure, Aortic Stenosis, and Pulmonary Hypertension. Tempus ECG-AF analyzes 12-lead ECGs to identify patients aged 65 or older at increased risk of developing new-onset atrial fibrillation/flutter (AF) within the next 12 months.

What type of patient data is required as input for each tool?

Us2.ai requires echocardiography data for its analysis. Tempus ECG-AF utilizes 12-lead ECG recordings, specifically compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.

Are there specific patient population criteria or exclusions for either tool?

Us2.ai is designed for general echocardiography analysis across various cardiac conditions. Tempus ECG-AF is intended for patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

How do these tools integrate with existing healthcare IT infrastructure?

Us2.ai offers extensive integration capabilities with ultrasound devices, PACS, CVIS, and EMR systems. Tempus ECG-AF is described as a software solution integrated into healthcare facility systems with advanced cardiology algorithms.

Is there specific reimbursement available for using these AI solutions?

Reimbursement details for Us2.ai are not publicly disclosed. Tempus ECG-AF has CMS reimbursement available, with CPT codes 0764T and 0765T mapping to APC 5734, and a Medicare rate of $128.90 effective January 1, 2025.

Which medical specialties are these tools primarily designed to support?

Us2.ai primarily supports Cardiology and Radiology specialties. Tempus ECG-AF is intended for use across Cardiology, Geriatrics, and Internal Medicine.